Movement Disorders

Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug

Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug

By

Tozadenant is being investigated as an adjunctive treatment to levodopa in Parkinson disease patients to reduce 'off' time.

Parkinson Disease Onset Linked to <i>LRRK2</i> Variants

Parkinson Disease Onset Linked to LRRK2 Variants

There is a younger age at onset of Parkinson disease linked with the presence of LRRK2 risk variants.

Patients With Parkinson Disease Are at High Risk for Depression

Patients With Parkinson Disease Are at High Risk for Depression

By

Female sex, dependency, high pain scores, and lower Mini-Mental State Examination scores were correlated with higher depression scores.

Cognitive Impairment in Multi-System Atrophy: Is It Time to Update Diagnostic Criteria?

Cognitive Impairment in Multi-System Atrophy: Is It Time to Update Diagnostic Criteria?

By

Although evidence of cognitive impairment in MSA is admittedly more limited than in Parkinson disease, it is now substantial enough to address modification of diagnostic criteria to include the potential for cognitive impairment at any stage of the disease.

Drug May Help Improve Daytime Sleepiness in Parkinson's

Drug May Help Improve Daytime Sleepiness in Parkinson's

Sodium oxybate seems to be effective for patients with Parkinson disease and excessive daytime sleepiness.

Orphan Drug Designation Granted to Valbenazine for Tourette Syndrome

Orphan Drug Designation Granted to Valbenazine for Tourette Syndrome

By

The primary endpoint of the study is the change from baseline of the Yale Global Tic Severity Scale between placebo and active treatment groups at the end of week 12.

Asleep Deep Brain Stimulation Linked to Better Outcomes in Parkinson's

Asleep Deep Brain Stimulation Linked to Better Outcomes in Parkinson's

By

Deep brain stimulation is traditionally conducted with the patient awake in order to help the ideal target for electrode placement.

Smoking Modifies Genetic Link to Parkinson Disease

Smoking Modifies Genetic Link to Parkinson Disease

Smoking may modify a genetic link with Parkinson disease.

Little Evidence Supports CSF α-Synuclein as a Diagnostic Tool for Parkinson Disease

Little Evidence Supports CSF α-Synuclein as a Diagnostic Tool for Parkinson Disease

By

The diagnosis of Parkinson disease is made mostly through a clinical assessment of motor signs and symptoms, which appear when approximately 70% of nigral neurons are lost.

Atypical Parkinsonian Disorders: Reviewing the Complex Web of Proteinopathies

Atypical Parkinsonian Disorders: Reviewing the Complex Web of Proteinopathies

By

While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.

AbobotulinumtoxinA Beneficial for Children With Lower Limb Spasticity

AbobotulinumtoxinA Beneficial for Children With Lower Limb Spasticity

By

Significant improvements in muscle tone, spasticity, goal attainment, and overall clinical benefit were observed across all injection cycles.

Compulsive Behavior Disorders Common in Patients With Parkinson Disease With Dyskinesia

Compulsive Behavior Disorders Common in Patients With Parkinson Disease With Dyskinesia

By

Patients with dyskinesia had a significantly higher frequency of impulse control disorders.

Prognostic Models for Predicting Death and Dependency in Parkinson's

Prognostic Models for Predicting Death and Dependency in Parkinson's

By

The investigators suggested that the models should be recalibrated based on geographic location for more individualized predictions.

Defining Unique Needs for Palliative and Hospice Care in Huntington Disease

Defining Unique Needs for Palliative and Hospice Care in Huntington Disease

By

Research has shown significant gaps in knowledge on palliative services among neurology residents, resulting in low referral rates.

Parkinsonism Diagnosis Linked to Cognitive Deficits

Parkinsonism Diagnosis Linked to Cognitive Deficits

By

Cognitive dysfunction may be a sign of prodromal Parkinson disease.

New Dose Approved for Tardive Dyskinesia Drug Ingrezza

New Dose Approved for Tardive Dyskinesia Drug Ingrezza

By

Ingrezza is a vesicular monoamine transporter 2 inhibitor, now available in an 80mg capsule.

Managing Dystonia With Noninvasive Brain Stimulation: Therapy Update

Managing Dystonia With Noninvasive Brain Stimulation: Therapy Update

By

There is speculation that dystonia is the result of dysfunction occurring in either the cerebellum or basal ganglia or as a result of an abnormal interaction between the two.

Cycling Overloads Movement Networks Impacted by Parkinson Disease

Cycling Overloads Movement Networks Impacted by Parkinson Disease

Abnormal beta synchrony in the Parkinsonian basal ganglia is suppressed by bicycling.

Parkinson Drugs With Highest Adverse Effect Rates

Parkinson Drugs With Highest Adverse Effect Rates

The highest incidence rates of adverse effects in PD were linked with ropinirole, bromocriptine, and piribedil.

Increased Parkinson's Risk Associated With Poor Sense of Smell

Increased Parkinson's Risk Associated With Poor Sense of Smell

A poor sense of smell is linked with an increased risk for Parkinson's disease.

β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD

β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD

β-2 adrenergic agonists might be able to fight Parkinson's disease.

Cerebellar Deficit in Dystonia Improved With Alcohol

Cerebellar Deficit in Dystonia Improved With Alcohol

Alcohol improves cerebellar-learning deficit in patients with myoclonus-dystonia.

Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability

Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability

By

Patients with postural instability and gait disturbances had worse sleep scores than those with tremor-dominant Parkinson's.

MRI in Parkinson Disease: Expanding Usability for Better Diagnostics

MRI in Parkinson Disease: Expanding Usability for Better Diagnostics

By

MRI may be used to identify Parkinson disease biomarkers that can inform diagnosis, track disease progression, and elucidate the neurobiological underpinnings of symptoms.

Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence

Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence

By

Given the prevalence of depression in Parkinson's disease and the effectiveness of antidepressants, health care providers should promote adherence in clinical practice.

Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease

Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease

By

Enrollment of patients with only early Parkinson's disease in this trial prevents generalization of the study's findings across the entire Parkinson's population.

Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline

Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline

By

Patients with both Parkinson's and rapid eye movement sleep behavior disorder were much more likely to experience mild cognitive impairment.

Levodopa-Induced Euphoria May Drive Addictions, Behavior in Parkinson's

Levodopa-Induced Euphoria May Drive Addictions, Behavior in Parkinson's

By

Patients taking levodopa therapy may experience neuropsychiatric fluctuations characterized by changes in mood, motivation, and anxiety while in ON and OFF states of drug therapy.

Remote Neurological Care a Feasible Option for Parkinson's Disease

Remote Neurological Care a Feasible Option for Parkinson's Disease

For patient's with Parkinson's disease, virtual house calls from neurologists may be of interest.

Patients With Intellectual Disability More Susceptible to Movement Side Effects of Antipsychotics

Patients With Intellectual Disability More Susceptible to Movement Side Effects of Antipsychotics

By

Incidence of neuroleptic malignant syndrome, akathisia, and parkinsonism was higher in the ID group.

Sign Up for Free e-newsletters

CME Focus